PRODUCT INFORMATION



Astilbin

Item No. 28267

CAS Registry No.:	29838-67-3	ОН
Formal Name:	(2R,3R)-3-[(6-deoxy-α-L-mannopyranosyl)	
	oxy]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-	OH
	5,7-dihydroxy-4H-1-benzopyran-4-one	
Synonym:	Taxifolin 3-O-rhamnoside	HO
MF:	$C_{21}H_{22}O_{11}$	
FW:	450.4	
Purity:	≥98%	Н Н
UV/Vis.:	λ _{max} : 292 nm	OH HO
Supplied as:	A crystalline solid	
Storage:	-20°C	но
Stability:	≥4 years	ОН
Item Origin:	Plant/Engelhardtia roxburghiana Wall.	011

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Astilbin is supplied as a crystalline solid. A stock solution may be made by dissolving the astilbin in the solvent of choice, which should be purged with an inert gas. Astilbin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of astilbin in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF.

Astilbin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, astilbin should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Astilbin has a solubility of approximately 0.1 mg/ml in a 1:10 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Astilbin is a flavonoid that has been found in S. glabra and has diverse biological activities.¹⁻³ It inhibits cisplatin-induced increases in apoptosis and accumulation of reactive oxygen species (ROS) in HEK293 cells when used at a concentration of 200 μ M.¹ Astilbin (50 mg/kg) increases renal glutathione (GSH) levels and superoxide dismutase (SOD) and catalase activity and reduces serum creatinine and blood urea nitrogen (BUN) levels, renal IL-1 β , IL-6, and TNF- α levels, apoptosis in kidney tissue, and kidney injury in a mouse model of cisplatin-induced nephrotoxicity. It reduces loss of dopaminergic neurons in the substantia nigra and increases striatal GSH levels and SOD activity in a mouse model of MPTP-induced Parkinson's disease when administered at a dose of 50 mg/kg per day.² Astilbin also reduces descent time in a pole test and increases traction test score in a mouse model of Parkinson's disease, indicating reduced motor deficits. It reduces cell viability of MDA-MB-231 and MCF-7 cells (IC₅₀s = 167.9 and 191.6 μ M, respectively), as well as inhibits migration and increases apoptosis when used at concentrations of 50 and 200 μ M.³ Astilbin (20 mg/kg every other day for 14 days) reduces tumor growth in an MCF-7 mouse xenograft model.

References

- 1. Wang, S.-w., Xu, Y., Weng, Y.-y., et al. Food Chem. Toxicol. 114, 227-236 (2018).
- 2. Zhu, Y.-L., Sun, M.-F., Jia, X.-B., et al. Int. Immunopharmacol. 66, 19-27 (2019).
- 3. Sun, X., Zhang, H., Zhang, Y., et al. Oncol. Rep. 40(4), 2278-2286 (2018).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/09/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM